tebotelimab
An Fc-bearing, humanized antibody-like protein that specifically recognizes the immune checkpoint molecules programmed cell death 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene-3 (LAG-3; LAG3; CD223), with potential T-lymphocyte immunomodulatory and antineoplastic activities. Upon administration, tebotelimab specifically binds to both PD-1 and LAG-3, which are both expressed on T cells. The dual blockade of the PD-1 and LAG-3 pathways enables potent activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation.
| Synonym: | anti-PD-1/anti-LAG-3 DART protein MGD013 bispecific DART protein MGD013 dual-affinity retargeting protein MGD013 PD-1 x LAG-3 bispecific DART molecule MGD013 PD-1 x LAG-3 DART molecule MGD013 PD-1 x LAG-3 DART protein MGD013 |
|---|---|
| Code name: | MGD 013 MGD-013 |